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Abstract
Antibiotic resistance is a growing threat worldwide, causing serious problems in the treatment of microbial infections. The
discovery and development of new drugs is urgently needed to overcome this problem which has greatly undermined the clinical
effectiveness of conventional antibiotics. An intricate cell-cell communication system termed quorum sensing (QS) and the
coordinated multicellular behaviour of biofilm formation have both been identified as promising targets for the treatment and
clinical management of microbial infections. QS systems allow bacteria to adapt rapidly to harsh conditions, and are known to
promote the formation of antibiotic tolerant biofilm communities. It is well known that biofilm is a recalcitrant mode of growth
and it also increases bacterial resistance to conventional antibiotics. The pharmacological properties of coumarins have been well
described, and these have included several that possess antimicrobial properties. More recently, reports have highlighted the
potential role of coumarins as alternative therapeutic strategies based on their ability to block the QS signalling systems and to
inhibit the formation of biofilms in clinically relevant pathogens. In addition to human infections, coumarins have also been
found to be effective in controlling plant pathogens, infections in aquaculture, food spoilage and in reducing biofouling caused by
eukaryotic organisms. Thus, the coumarin class of small molecule natural product are emerging as a promising strategy to combat
bacterial infections in the new era of antimicrobial resistance.
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Introduction
The indiscriminate use of antibiotics has brought us to the
brink of a new era where the emergence of multidrug-
resistant bacterial and fungal pathogens poses one of the
major health issues of global concern (Fernandez and
Hancock 2012; Tanwar et al. 2014). The rapid decline in
the discovery of novel antibiotics in the last two decades
has coincided with the emergence of resistance to all
known classes of clinically used antibiotics. While the ur-
gent need to discover and develop novel strategies to com-
bat microbial infections is recognised, how this is best
achieved is less clear. The case for growth-limiting antibi-
otics remains strong, and decorated derivatives of existing
antibiotics continue to make it to the clinic. However, with
the possible exception of the newly discovered teixobactin
(Ling et al. 2015), resistance to newly introduced antibi-
otics is likely to emerge in the short rather than the long
term. A particularly notable case is the recent reports of
resistance to the polymyxin class of antibiotic, long
regarded a salvage therapy for which transmissible resis-
tance was unlikely to emerge. This was largely due to the
fact that polymyxins target the cell membrane, and there-
fore plasmid-encoded resistance would be more difficult to
achieve. However, reports from China and the USA have
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confirmed the transmission of plasmid-encoded resistance
among Escherichia coli isolates (Liu et al. 2016).
Owing largely to the challenges associated with antibi-
otic resistance and the dearth of new antibiotics in the
development pipeline, researchers have pursued alterna-
tive strategies to manage microbial infections. One of the
best developed of these are strategies that target a micro-
bial signalling system termed quorum sensing (QS)
(Cegelski et al. 2008; Cooper and Shlaes 2011; LaSarre
and Federle 2013). QS is a cell to cell communication
signalling system that controls the expression of, in some
cases, hundreds of genes related to virulence phenotypes
in clinical human pathogens (Papenfort and Bassler 2016).
QS regulons are known to vary between species, as indeed
does the spectrum of virulence-related phenotypes that
falls under QS control (Whiteley et al. 2017). Biofilm for-
mation is one of the most important virulence phenotypes
of opportunistic human pathogens, and it is under the con-
trol of the QS system in several important pathogenic or-
ganisms. A structured community of bacteria that requires
intact cell-cell communication for its initiation and matu-
ration, the biofilm lifestyle poses a significant challenge to
the effectiveness of conventional antibiotics and is consid-
ered a breeding ground for antibiotic resistance (Hoiby
et al. 2011). In recent years, increasing attention has been
paid to finding novel therapeutic strategies specifically
targeting QS signalling systems and the biofilm mode of
growth, providing the pillar upon which the future of next-
generation antivirulence therapies would be forged (de la
Fuente-Nunez et al. 2014; Kalia 2013; Njoroge and
Sperandio 2009). Sourcing these compounds has followed
quite diverse paths with bioprospecting of natural ecosys-
tems and synthetic remodelling occurring separately and
as integrated endeavours. Plant phenolics have delivered a
broad range of bioactive compounds, many of which are
now being considered for their anti-infective potential.
The bioactive potential of different environments and
their associated organisms have been established over the
last number of decades, with soil and more recently marine
life proving to be a rich source of novel compounds that
may be exploited as QS inhibitors and antibiofilm agents
(Gutierrez-Barranquero et al. 2017; Kalia 2013; Manefield
et al. 2002; Miquel et al. 2016; Rabin et al. 2015;
Rasmussen et al. 2005; Sayem et al. 2011). Plant second-
ary metabolites, and specifically plant phenolic com-
pounds (Slobodnikova et al. 2016), have been widely used
for decades because of their great pharmacological prop-
erties (Venugopala et al. 2013). Coumarins are a large
family of naturally derived fused benzene and a-pyrone
rings found primarily in a wide range of plant sources.
Some coumarins are regarded as phytoalexins which are
plant resistance compounds that are biosynthesised by
plant tissues in response to pathogenic infection (Yang
et al. 2017). Members of the coumarin class of compound
have also been identified in bacteria and fungi, such as
novobiocin and coumermycin isolated from Streptomyces
(Eustaquio et al. 2003), and aflatoxins isolated from dif-
ferent Aspergillus species (Kumar et al. 2016).
The role of coumarins as antimicrobial molecules has been
extensively studied to date (Al-Majedy et al. 2016) with com-
pounds having long chain hydrocarbon substitutions being
particularly active (Venugopala et al. 2013). Among many
other relevant therapeutic activities, coumarins are notable
for their role as anticancer, anti-inflammatory, antimicrobial,
anti-oxidant and anticoagulant bioactive compounds (Joubert
et al. 2017; Kapp et al. 2017; Mandlik et al. 2016; Venugopala
et al. 2013). Structurally, these naturally produced coumarins
comprise a diverse spectrum of modifications from the parent
molecule (Murray 2002), with pyrano- and furano-coumarins
being particularly pharmacologically active. However, some-
what surprisingly, the parent molecule coumarin possesses
very low antibacterial activity, in contrast to its decorated
counterparts. Rather than being biologically inactive, it would
appear that coumarin plays a more subtle role in the natural
ecosystem, one where governance of microbial behaviour is
controlled through suppression of QS signalling and the for-
mation of biofilms (Fig. 1). Recent reports on the role of
coumarins as QS inhibitors and antibiofilm agents
(Gutierrez-Barranquero et al. 2015; Lee et al. 2014) have
drawn the attention of many research groups to the potential
of coumarin as a natural non-toxic anti-infective. This review
provides an insight into the bioactivity of the coumarin class
of plant phenolics with particular emphasis on the emerging
role of coumarin as a novel QS inhibitor and antibiofilm agent
across a broad spectrum of microbial pathogens.
Coumarins from diverse ecological sources possess
potent antimicrobial activity
Plant extracts have long been known to possess beneficial
activities for human health, and have been used since an-
cient times as medicines, particularly in Oriental cultures.
Although the basis of these health-promoting properties is
still only partly understood, the effectiveness of plant ex-
tracts as sources of lead compounds for modern drug de-
velopment underpins the importance of these natural
sources of bioactive compounds. Apart from the develop-
ment of potent therapeutics for the treatment of cancer,
inflammation and other clinical conditions, plant extracts
have also provided a range of compounds that target mi-
crobial pathogens. The coumarin class of phenolic com-
pound derived from plant extract have received consider-
able attention based on their antimicrobial properties, and
are emerging as a promising candidate for next generation
antimicrobial development.
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The antibacterial and anti-oxidant activities of several
coumarins and pyranocoumarins isolated from the roots
of Ferulago campestris were reported against gram-
negative and gram-positive pathogens. These included
Staphylococcus aureus, Salmonella enterica serovar
Typhi, Enterobacter cloacae and Enterobacter aerogenes
(MIC 16–32 μg/mL) as well as the digestive tract pathogen
Helicobacter pylori (MIC 5–25 μg/mL) (Basile et al.
2009). Similarly, Prangos hulusii root extracts yielded a
new prenylated coumarin in addition to nine that were pre-
viously characterised. The root extract and its prenylated
coumarins were found to exhibit antimicrobial activity
against clinical pathogens including Bacillus subtilis and
Klebsiella pneumoniae (MIC 5–125 μg/mL) (Tan et al.
2017). Methanol extracts prepared from seven plants
grown in Finland were found to produce antimicrobial ac-
tivity against bacterial and fungal pathogens, although the
activities of six natural coumarin compounds were report-
edly weak, with the exception of the inhibitory effect
against the fungal pathogen Fusarium culmorum (Ojala
et al. 2000). Three new coumarin derivatives and three new
furanocoumarins were isolated from the fern Cyclosorus
interruptus (Willd.) H. Itô (Quadri-Spinelli et al. 2000). One
of the former and two of the latter were found to possess
antibacterial activity. An aryl coumarin glucoside, asphodelin
A 4’-O-β-D-glucoside, isolated from Asphodelus
microcarpus exhibited antibacterial activity against
S. aureus, E. coli and Pseudomonas aeruginosa as well as
modest antifungal activity against the fungal pathogens
Candida albicans and Botrytis cinerea (El-Seedi 2007).
Interestingly, the bulbs and roots of A. microcarpus have long
been used by Bedouin tribes as an antimicrobial agent. Kayser
and Kolodziej working with simple coumarins described
broad diversity regarding growth inhibitory activity with min-
imum inhibitory concentrations ranging from 0.9 to >
12.4 μM (Kayser and Kolodziej 1999). Pathogens tested in-
cluded S. aureus, beta-hemolyt ic Streptococcus,
Streptococcus pneumoniae, E. coli, K. pneumoniae, P.
aeruginosa, Proteus mirabilis and Haemophilus influenzae.
While coumarins with a methoxy function at C-7 and, if pres-
ent, an OH group at either the C-6 or the C-8 position were
invariably effective, the presence of an aromatic dimethoxy
arrangement was found to be favourable against those micro-
organisms which require special growth factors (beta-
haemo ly t i c S t rep tococcus , S . pneumon iae and
H. influenzae). However, in spite of the broad range of activity
of coumarin compounds, the simple coumarin structure itself
has very low antibacterial activity. The reason for this loss of
activity in the absence of long hydrocarbon chains or other
decorations is not yet understood. However, recent reports
have suggested that, rather than limiting the growth of micro-
bial pathogens, coumarin itself can target a key microbial cell-
cell communication system and with it, the ability to inhibit
antibiotic tolerant colonisation structures called biofilms.
Fig. 1 The coumarin class of plant phenolic compound have been shown
to possess several important pharmacological properties. More recently, a
role in the modulation of microbial behaviour has emerged, with several
reports describing interference with cell-cell communication (quorum
sensing) and the formation of multicellular microbial structures
(biofilms). Particular emphasis has been placed on the ability of
coumarins to disrupt AI-1 and AI-2 signalling in a range of important
microbial pathogens
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Coumarins as anti-QS and antibiofilm agents
against clinically relevant pathogens
Coumarins were first considered as potential anti-QS and
antibiofilm compounds following a virtual QS inhibitor screen
of a Traditional Chinese Medicine library by docking analysis
against the Agrobacterium tumefaciens QS transcriptional ac-
tivator protein TraR (Zeng et al. 2008). This study revealed
that esculetin (6,7-dihydroxycoumarin) and esculin were
structurally compatible with the TraR signal binding site.
Although this study did not explore the QS inhibitory function
experimentally, the authors did demonstrate that both couma-
rin derivatives were able to inhibit the P. aeruginosa biofilms
at a concentration of 200 μM. In a separate study, Brackman
and colleagues showed that both of these molecules have a
moderate ability to suppress the biofilm formation of two spe-
cies of the Burkholderia cepacia complex (Brackman et al.
2009). Moreover, in this case, the authors were able to dem-
onstrate inhibition of QS signalling using biosensor reporter
strains (Brackman et al. 2009). Two furocoumarins isolated
from grapefruit juice, bergamottin and dihydroxybergamottin,
were able to suppress QS biofilm formation in E. coli
O157:H7 up to 72 and 58.3%, respectively (Girennavar
et al. 2008). Antibiofilm activity of these compounds against
S. enterica serovar Typhimurium (15.5 and 46.5%, respective-
ly) and P. aeruginosa (18.1 and 27.3%, respectively) was
more modest (Girennavar et al. 2008). In this latter study,
the authors demonstrated how both furocoumarins were able
to inhibit AI-1 (N-acyl homoserine lactones, AHLs) and AI-2
(furanosyl borate diester) signalling using Tn5 mutants of
Vibrio harveyi as reporter strains. Following this, an interest-
ing study conducted by Durig et al. (2010) using a chemo-
informatic approach targeting the Chinese natural product da-
tabase (CNPD) developed a series of 2nd and 3rd generation
compounds from ellagic acid using a coumarin scaffold.
Esculetin (2nd generation) was found to be a potent
antibiofilm agent towards S. aureus strain 8324, but did not
affect biofilm formation of S. aureus NCTC4671 or ATCC
27957. The 3rd generation compound fisetin was shown
to be active against all three strains (Durig et al. 2010). A
virtual docking approach also identified nodakenetin and
fraxin (two coumarin compounds extracted from
Peucedanum decursivum (Miq). Maxim and Fraxinus
chinensis Roxb., respectively) as putative QS inhibitors,
with the antibiofilm ability of both subsequently demon-
strated in Pseudomonas aeruginosa and to a lesser extent
Stenotrophomonas maltophilia (Ding et al. 2011).
More recently, attention has switched to the simple couma-
rin compound, with several studies revealing a broad spectrum
of antivirulence activity. Lee et al. (2014) carried out a screen
of 560 phytochemicals to identify new antibiofilm compounds
against E. coli O157:H7. Restricting the second round of
screening only to hits where the biofilm reduction was above
70%, only four compounds met the requirement, one of them
being a sesquiterpene coumarin (Lee et al. 2014). Following
this, the authors subsequently investigated the role of eight
different coumarins [coumarin, coumarin-3-carboxylic acid,
dephnetin, ellagic acid, esculetin, 4-hydroxycoumarin,
scopoletin and umbelliferone (7-hydroxycoumarin)] for
antibiofilm activity against the E. coli O157:H7 strain.
Similar to coladonin, coumarin and umbelliferone showed
the highest biofilm inhibition, reaching values of 80 and
90%, respectively. qRT-PCR analysis revealed that neither
compound impacted on AI-2 signalling, with expression of
the luxS gene encoding the synthase responsible for AI-2
production being unaffected in the presence of either cou-
marin or umbelliferone. However, expression of the QS-
controlled lsrA gene was decreased in response to either
compound. As such, the anti-QS activity of these coumarin
compounds remains to be determined, as does its role if any
in the biofilm suppression activity of coumarins against this
important human pathogen.
Confirmation of the QSI activity of coumarin came from a
study by our own group in 2015 where we analysed the QS
mode of action of coumarin with a combination of direct and
signal competition biosensor assays (Gutierrez-Barranquero
et al. 2015). The QS inhibition biosensor reporter strains
Serratia marcescens SP15, Chromobacterium violaceum
DSM 30191 A. tumefaciens NTL4 all showed pigment inhi-
bition in the presence of increasing concentrations of couma-
rin. These findings were independent of any growth-related
effects. In addition, signal competition assays using the QS
biosensor reporter strains S. marcescens SP19, C. violaceum
CV026 and A. tumefaciens NTL4 (adding specific AHLs)
suggested an AHL-specific interference. In order to further
establish the QSI activity of coumarin, and to determine
whether or not it extended to a clinically relevant pathogen,
P. aeruginosa PA14 was selected for analysis. Coumarin de-
creased the expression of the QS-related genes pqsA and rhlI
in Pseudomonas aeruginosa PA14. Coumarin also inhibited
biofilm formation in this pathogen, along with several other
virulence phenotypes including swarming motility and phen-
azine production. The broad-spectrum activity of coumarin
was revealed by demonstrating inhibition of biofilm formation
of other gram-negative and gram-positive bacteria (E. coli,
Edwardsiella tarda, Vibrio anguillarum and S. aureus), pro-
tease activity (S. maltophilia and B. cepacia) and biolumines-
cence (Allivibrio fischeri). Taken together, these data support a
role for coumarin in the suppression of QS and biofilm for-
mation in clinically relevant pathogens (Fig. 2). However,
further mechanistic studies will be required before coumarin
can be considered a universal QS and biofilm inhibitor. This is
particularly true in light of the multitude of QS systems in
different bacterial species affected and the current lack of mo-
lecular mechanism to explain the possible anti-QS and
antibiofilm effects of coumarin.
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Warfarin an important coumarin derivative that is widely
used as an oral anticoagulant agent worldwide (Pirmohamed
2006) was tested for antibiofilm activity against E. coli and
found to reduce biofilm formation by 40% when tested at
7.5 mM (Ojima et al. 2016). A lower concentration of 5 mM
warfarin did not significantly impact biofilm formation
(Ojima et al. 2016). In the same study, lactoferrin (a milk
protein that shows a wide range of biological properties, in-
cluding antimicrobial function) and ampicillin (a β-lactam
antibiotic) were shown to promote biofilm formation in
E. coli when administered at subinhibitory concentrations.
Interestingly, the authors demonstrated that in the presence
of either compound, warfarin significantly decreased biofilm
formation of E. coli by 50% at a concentration of 5 mM. This
study adds another layer of complexity to the mode of action
of coumarins, supporting the idea that some could impact
biofilm formation promoted by subinhibitory concentrations
of other molecules.
Non-clinical biotechnological applications
of coumarin QSI and antibiofilm activity
As might be expected, the role of coumarins in QSI and bio-
film formation inhibition has been typically tested in human
bacterial pathogens that cause serious health problems in hos-
pitals. However, recent studies have also exploited the anti-QS
and antibiofilm properties of coumarins in other systems.
Fig. 2 A schematic overview of
coumarin structures and their anti-
infective properties. Compounds
for which anti-biofilm properties
have been established are
presented on the left, while those
with dual activity are presented on
the right
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Bacterial wilt a disease elicited by R. solanacearum pro-
duces severe economic losses to important crops such as to-
mato, potato, tobacco and eggplant in tropical and subtropical
regions worldwide. As coumarins have been reported previ-
ously for their antibacterial activities (Barot et al. 2015), 18
different coumarin derivatives including some hydroxylated
variations were tested for antibacterial and antibiofilm activity
against R. solanacearum (Yang et al. 2016). From the 18 cou-
marin tested, 4 of them showed the highest biofilm formation
inhibition, coumarin, and three different hydroxycoumarins
(umbelliferone, esculetin and dephnetin). It is worth noting
that the best antimicrobial activities were also displayed by
these same coumarins, raising the possibility that the biofilm
suppression may simply reflect the limitation of growth under
these conditions. The authors subsequently followed up this
study with analysis of umbelliferone and its antivirulence ac-
tivity against R. solanacearum (Yang et al. 2017). The type
three secretion system (T3SS) and biofilm formation were
both suppressed.
Marine biofouling is the accumulation of micro- and
macro-organisms on submerged structures in seawater.
Currently, it is a persistence problem that causes severe eco-
nomic losses and also has an impact from an ecological point
of view (Callow and Callow 2011). A recent study described
the role of 7-hydroxy-4-methylcoumarin as an effective agent
against biofouling, inhibiting both the settlement as well as the
byssogenesis of mussels (Perez et al. 2016). Although the role
of coumarin as a novel QS inhibitor has been demonstrated
previously (Gutierrez-Barranquero et al. 2015), there was no
attempt to explore whether coumarin could be used as a pro-
tective treatment in aquaculture. In this sense, Zhang and
coworkers (2017) analysed the protective role of coumarin
in relation to infection by Vibrio splendidus in an aquaculture
model of Apostichopus japonicas (Zhang et al. 2017). The
authors observed that coumarin could interfere with the induc-
tion of QS-regulated virulence genes by cell-free supernatants
and ethyl acetate extracts of V. splendidus shown to possess
AHLs by activation of C. violaceum CV026. Thus, they pro-
posed that coumarin could be used as a QS inhibitor to possi-
bly modulate V. splendidus infections in future aquaculture
applications. The authors also reported that coumarin did not
exhibit any effect on biofilm formation, possibly due to the
fact that V. splendidus showed poor ability to develop in vitro
biofilms on polystyrene microtitre plates (Zhang et al. 2017).
Finally, Hou and coworkers analysed the ability of
dihydrocoumarin to inhibit the biofilm formation of Hafnia
alvei, a bacterium that is mainly found in spoiled food (Hou
et al. 2017). Biofilm formation in this organism has previously
been linked to QS, although its contribution to persistence and
spoilage per se remains to be fully elucidated (Viana et al.
2009). The authors demonstrated the capacity of
dihydrocoumarin in the inhibition of violacein production by
C. violaceum CV026, and also, observed a high impact on the
reduction of biofilm formation at approximately 90%. These
findings indicate that dihydrocoumarin could be a useful QS
inhibitor or antibiofilm agent for potential development in
controlling food spoilage organisms (Bai and Rai 2011).
Structure-function analysis of the QSI
and antibiofilm activity of coumarins
Previous studies had investigated structure-function relation-
ships of coumarins linked to antibacterial activity. As couma-
rin has been identified as a potent antivirulence molecule, and
because different substitutions in specific sites of the coumarin
molecule can affect its biological activity (Barot et al. 2015), a
SAR analysis was a logical undertaking in relation to under-
standing QSI and antibiofilm activity. D'Almeida et al. (2017)
followed such an approach to test if the different substitutions
on the coumarin structure could affect the QSI activity
(D'Almeida et al. 2017). Using P. aeruginosa and
C. violaceum as test species, D’Almeida and colleagues
(D'Almeida et al. 2017) performed a comparison of seven
structurally related coumarins (coumarin and different hy-
droxylated derivatives). Initially using a bioassay with the
QS biosensor C. violaceum CV026, and adding exogenous
hexanoyl homoserine lactone (HHL), the authors demonstrat-
ed that all the different coumarins tested, with the exception of
4-hydroxycoumarin and dihydrocoumarin, were able to inhib-
it the violacein production. In a follow-up test using
C. violaceum ATCC 12472, the authors observed that both
4-hydroxycoumarin and dihydrocoumarin were indeed able
to reduce the percentage of violacein production, although to
a lesser extent compared to the other coumarins tested. Finally,
the authors tested the capacity of the different coumarins to
inhibit biofilm formation of P. aeruginosa. Esculetin,
umbell i ferone and coumarin showed the highest
P. aeruginosa biofilm inhibition, while 4-hydroxycorumarin
and dihydrocoumarin presented the lowest activity in this re-
gard. This contrasts with the relatively low antibiofilm activity
of esculetin towards E. coli described by Lee et al. (2014), and
suggests that species or strain heterogeneity may play some
role in this response. The low activity associated with hydrox-
ylated coumarins has previously been reported in E. coli with
respect to biofilm formation (Lee et al. 2014). Hydroxylation
at position 4 or position 8 (dephnetin) of the coumarin struc-
ture was found to dramatically diminish antibiofilm activity
while the same modification at position 7 led to enhanced
activity. Di-hydroxylation of coumarin at positions 6 and 7
(esculetin) led to a reduction in activity compared to simple
coumarin in this study. Replacing the 6-hydroxy group with a
6-methoxy group (scopoletin) did not affect antibiofilm activ-
ity, while decoration at position 3 with a carboxy group di-
minished activity compared with the parent compound (Lee
et al. 2014). The introduction of a sesquiterpene in position 7
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(coladonin) neither enhanced nor diminished activity with re-
spect to coumarin.
Structural modifications of the coumarin framework have
also been undertaken with the aim of developing more effec-
tive pharmacologically active coumarins (Saleem et al. 2010).
Several synthetic coumarins with a variety of pharmacophoric
groups at C-3, C-4 and C-7 positions have been intensively
screened for antimicrobial, anti-HIV, anticancer, lipid-lower-
ing, anti-oxidant and anticoagulation activities (Kulkarni et al.
2006). Hydroxylation of coumarins at the C-6, C-7 or C-8
position was shown to significantly enhance the antibacterial
activity against R. solanacearum (Yang et al. 2016). Guan and
coworkers showed that decoration of the coumarin framework
with methoxyacrylate moieties derived from natural
strobilurin A can generate possible lead compounds for devel-
oping novel fungicides (Guan et al. 2011). Potent antimicro-
bial and anti-inflammatory activities have been described for
C4-substituted aryloxymethyl, arylaminomethyl and
dichloroacetamidomethyl coumarins, along with the corre-
sponding 1-azacoumarins (Kulkarni et al . 2006).
Kalkhambkar and colleagues reported the synthesis of a series
of new fluorinated coumarins and 1-aza coumarins
(Kalkhambkar et al. 2008). Introduction of fluorine at the 4′-
position in the aryloxy and arylamino moieties of both cou-
marin and 1-aza-coumarin was found to enhance the antimi-
crobial properties of the compounds. Analgesic and anti-
inflammatory properties were also enhanced in these modified
compounds. More recently, a series of novel coumarin–benz-
imidazole hybrids were designed and synthesised.
Compounds showed broad-spectrum antibacterial activity
against P. aeruginosa, S. aureus, Bacillus subtilis and
P. vulgaris (Singh et al. 2017).
Conclusion and future challenges
The importance of developing new anti-infective compounds
with a real possibility of clinical use is underscored by recent
reports of a severe lack of pipeline compounds with antimi-
crobial activity. Not alone is antibiotic resistance on the in-
crease, and the discovery of new antibiotics long since passed
into rapid decline, but the introduction of new chemical enti-
ties has also plateaued (Reen et al. 2015). Therefore, there is
an urgent need to develop innovative new compounds that can
either (i) directly address the threat of superbugs and resistant
pathogens or (ii) enable conventional antibiotics to do so.
Over the last decade, coumarins have received considerable
attention in this regard, being isolated from natural sources,
chemically decorated or synthetically derived. Apart from
exhibiting antibacterial, antifungal and antiviral activity, sev-
eral members of the coumarin class of compound target cell-
cell signalling through QSI, and the aggregation of multicel-
lular communities of biofilms (summarised in Table 1). Future
studies will no doubt focus on improved properties from the
perspective of increased bioactivity and clinical compatibility.
However, understanding the role of these compounds in their
natural ecosystem may also uncover new applications for this
biotechnologically important class of molecule.
From the perspective of understanding the ecological role
of coumarins, focus and attention will naturally veer towards
the rhizosphere interactome where these compounds are
thought to play a considerable role. Exuded from the roots
of plants, the antibacterial and antifungal activity of coumarins
is thought to affect the dynamics of the resident microbiota,
and its interplay with other constituents of this rich ecosystem
with high species richness. However, while we often view
antimicrobials as weapons, whether this is the case in a natural
ecosystem, or whether the low concentrations act as signals
remains to be established. In this sense, the QSI and
antibiofilm activity for coumarins, and the structural spec-
ificity that underpins this activity, could reflect a more
subtle role for these compounds in situ. The aforemen-
tioned activities would enable the plant to moderate local-
ised microbiota with a lesser threat of resistant pathogens
adapting to the growth-limiting activity of its antimicrobial
counterparts. It is also possible that the presence of QSI
and antibiofilm compounds in the rhizosphere may in-
crease the effectiveness of antimicrobials, restricting mi-
crobes to planktonic antibiotic susceptible growth.
The molecular mechanism by which coumarins effect their
QSI and antibiofilm activity remains to be determined. While
suppression of QS could explain some of the antibiofilm ac-
tivity, the interactions that govern this impact remain
uncharacterised. It is also worth noting that coumarins can
disrupt both AI-1 and AI-2 signalling in some cases, both
structurally distinct systems for which a unifying principle
remains to be elucidated. From the perspective of biofilm
inhibition, the ability of coumarin to interfere with biofilms
in both gram-negative and gram-positive pathogens suggests
that QS signalling alone is unlikely to explain its mechanism
of action. In some cases, growth-limiting effects of coumarins
cannot be ruled out. The coumarin concentrations used in
these studies ranged from 1 μg/ml (Girennavar et al. 2008)
to 1.5 mg/ml (Ojima et al. 2016), with limited investigation of
the impact of these active compounds on the growth of target
pathogens. Both biofilm and QS are cell density-dependent
multicellular phenotypes, and as such can be significantly al-
tered by reductions in growth rate or biomass. Therefore,
growth kinetic assays and dose dependency curves will be
needed to establish the growth independence and true QS
and biofilm inhibitory activity of these compounds.
Furthermore, while some of the studies cited used analytical
technologies such as liquid chromatography mass spectrome-
try and thin layer chromatography for QS detection, several
studies relied solely on activation or suppression of pigment
production in classical biosensor strains. Although widely
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used for the identification of QS producing/inhibiting isolates,
off-target effects have been reported, highlighting the need for
confirmatory analysis (Defoirdt et al. 2013). Therefore, it is
clear that further studies on the mechanism are needed to
support the ongoing development of derivative compounds
towards clinical use.
From a pharmacological perspective, the applicability of
coumarin in clinical applications would appear to be
favourable. Although liver toxicity in rodents has been report-
ed (Felter et al. 2006), and cancerogenic activity was reported
in early studies on the simple coumarin structure (Lake 1999),
coumarin is not genotoxic. Therefore, exposure to coumarin in
food or cosmetics products is not thought to pose any risk to
humans (Lee et al. 2014). A therapeutic dose of 0.64 mg/kg of
body weight is considered safe and will guide the clinical
application of these compounds going forward (Felter et al.
2006). Hence, structure-function studies and chemical modi-
fications linked to improved bioactivity will be crucial in en-
suring that these compounds can be brought through clinical
testing and find application in the management of infections.
This is by no means a foregone conclusion and it should be
noted that despite almost 20 years of research into QSI and
antibiofilm compounds, the commercial route to the clinic for
these promising molecules has yet to be reached. The natural
Table 1 Coumarin targets QS and biofilm formation in pathogenic bacteria
Coumarin compound Target organism Conc (μg/ml) QSI Antibiofilm Reference
Coumarin E. coli O157:H7 50 lsrA +++ (Lee et al. 2014)
Umbelliferone E. coli O157:H7 50 lsrA +++
Coladonin E. coli O157:H7 50 +++
Coumarin-3-carboxylic acid E. coli O157:H7 50 ++
Dephnetin E. coli O157:H7 50 ++
Ellagic acid E. coli O157:H7 50 ++
Esculetin E. coli O157:H7 50 ++
4-Hydroxycoumarin E. coli O157:H7 50 ++
Scopoletin E. coli O157:H7 50 ++
Coumarin P. aeruginosa 200 rhl, pqsA ++ (Gutierrez-Barranquero
et al. 2015)Coumarin Edwardsiella tarda 200 +
Coumarin E. coli MUH 200 ++
Coumarin S. aureus NCDO949 200 ++
Coumarin V. anguillarum 200 ++
Coumarin A. fischeri 200 Bioluminescence
Dihydroxybergamottin V. harveyii 1 BB886 luxP Tn5 (Girennavar et al. 2008)
BB170 luxN Tn5
Bergamottin V. harveyii 1 BB886 luxP Tn5
BB170 luxN Tn5
Dihydroxybergamottin E. coli 1 +++
Bergamottin E. coli 1 +++
Dihydroxybergamottin S. typhimurium 1 +
Bergamottin S. typhimurium 1 ++
Dihydroxybergamottin P. aeruginosa 1 +
Bergamottin P. aeruginosa 1 ++
Esculetin S. aureus 8324 128 +++ (Durig et al. 2010)
Fisetin S. aureus 8324 16 +++
Fisetin S. aureus NCTC 16 +++
Fisetin S. aureus ATCC 16 +++
Nodakenetin P. aeruginosa 81 +++ (Ding et al. 2011)
Nodakenetin S. maltophilia 81 ++
Fraxin P. aeruginosa 74 ++
Fraxin S. maltophilia 74 +
Umbelliferone R. solanocearum 50 +++ (Yang et al. 2017)
Coumarin V. splendidus 985 Vsm, Vsh (Zhang et al. 2017)
Warfarin E. coli 1540 ++ (Ojima et al. 2016)
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product status of coumarins and their relatively benign toxic-
ity may help to bridge this gap.
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